← Leaderboards
Ian Gurrell
Astrazeneca Pharmaceuticals, Lp
$5,256,914
Attributed
$5,256,914
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2022–24$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
Funding mix
By agency
NIH$5,256,914 · 2
By mechanism
UH3$3,024,162 · 1
UG3$2,232,752 · 1
Top collaborators
No co-investigators on record.
Most similar at Astrazeneca Pharmaceuticals, Lp
Same institution · by research overlap
- Thor Ostenfeld$1,516,338
- Fiona J. Thomson$1,516,338
Others in their field
Other Rising Stars on “Clinically Significant”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Mari Ostendorf · University Of Washington$51,931,230
- Jennifer Lee O'Brien · University Of South Florida$15,110,862
- Maximilian Haeussler · University Of California Santa Cruz$12,592,563
- Sabrina Paganoni · Massachusetts General Hospital$11,004,714
- Suma Babu · Massachusetts General Hospital$11,004,714
Research focus
Clinically SignificantClinical ResearchClinicAddictionAntagonistAdverse EventAbstinenceAttenuatedAnimal ModelBehaviorBehavioralBiological AvailabilityBloodAnxietyArousalAgedBuprenorphineCanis FamiliarisCarbon DioxideCerebrospinal FluidCessation Of LifeChemistryCircadianCohort
Grant awards (2)
A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder.$3,024,162
UH3 · FY2024 · DA · contact PI
A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder.$2,232,752
UG3 · FY2022 · DA · contact PI